Evidence map›Paper›PMID 40688682›Full record

ArticleMaterials today. Bio2025

Fe-doped MOF nanoparticles: the LIFR and BMP4 dual-signaling pathways activated regulator for in vitro expansion of mouse embryonic stem cells.

Youyuan Li, Hong Wang, Zhilei Li, Huichao Wang, Yi Gao, Chaoran Wu, Bangguo Wei, Zhanyun Guo, Xijin Wang, Guoxin Jing and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Youyuan LiResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.
Hong WangResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.
Zhilei LiResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.
Huichao WangResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.
Yi GaoResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.
Chaoran WuResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.
Bangguo WeiResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.
Zhanyun GuoResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.
Xijin WangDepartment of Neurology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, PR China.
Guoxin JingResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.
Shilong WangResearch Center for Translational Medicine at East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the cultivation of mouse embryonic stem cells (mESCs), leukemia inhibitory factor (LIF) and mitotically inactive mouse embryonic fibroblasts (MEFs) are usually used to maintain the self-renewal and pluripotency of mESCs. However, the high cost of LIF and the immunogenicity of MEFs limit their clinical application in stable culture and large-scale expansion of mESCs. Therefore, it is necessary to pursue a low-cost, convenient, and safe alternative. This study found that Fe-doped metal organic framework nanoparticles (Fe MOF) have good biocompatibility under long-term cultivation and could maintain the self-renewal of mESCs in the absence of LIF and MEFs, without destroying the potential of mESCs to differentiate into three germ layer cells. Through transcriptome sequencing, it was demonstrated that Fe MOF nanomaterials could not only upregulate the expression of LIFR/GP130, but more importantly, they could activate the Fe

Indexed as

Embryonic stem cellsFe MOF nanomaterialsLIFR and BMP4 signaling pathwaysSelf-renewal and pluripotency

Identifiers

PMID40688682
PMCPMC12275132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.